Apellis
Ophthalmology & Eye Clinics · Biologics & Biosimilars

Apellis news and milestones

Apellis: 7 headlines on record, 0 headlines in the last 90 days.

Data updated Nov 13, 2026 · Back to the company report
7Headlines
0In 90 days
0Milestones

Headlines

Dec 12, 20252025
Jul 9, 20252025
News · YahooFinance
Apellis Sells Aspaveli Ex-US Royalties to Sobi for Up to $300M
Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is one of the most promising stocks according to Wall Street analysts. On July 1, Apellis Pharmaceuticals announced a capped royalty pu…
Jun 30, 20252025
News · Nasdaq
Apellis Pharmaceuticals Secures $275 Million Upfront Financing and $25 Million in Milestones for Aspaveli in Rare Kidney Diseases
Apellis secures $275 million upfront and potential $25 million in milestone payments from Sobi, enhancing financial strengths for kidney disease treatment.
Mar 5, 20252025
Nov 6, 20242024
News · The Motley Fool
Why Apellis Pharmaceuticals Stock Was Tumbling on Tuesday
Sales of the company's top commercialized product didn't meet expectations.
Oct 28, 20242024
Sep 20, 20242024
Sources: the outlets named on each headline, each story once

How to cite

Apellis, News. Alion, Nov 13, 2026. https://alion.io/company/apellis-com/news

.json · .md · CC BY-SA 4.0